AU3255897A - Inhibition of hiv-1 replication by antisense rna expression - Google Patents

Inhibition of hiv-1 replication by antisense rna expression

Info

Publication number
AU3255897A
AU3255897A AU32558/97A AU3255897A AU3255897A AU 3255897 A AU3255897 A AU 3255897A AU 32558/97 A AU32558/97 A AU 32558/97A AU 3255897 A AU3255897 A AU 3255897A AU 3255897 A AU3255897 A AU 3255897A
Authority
AU
Australia
Prior art keywords
hiv
replication
inhibition
antisense rna
rna expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU32558/97A
Other versions
AU717233B2 (en
Inventor
Ernst Boehnlein
Sonia Escaich
Heini Ilves
Gabor Veres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Systemix Inc
Original Assignee
Ciba Geigy AG
Novartis AG
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG, Systemix Inc filed Critical Ciba Geigy AG
Publication of AU3255897A publication Critical patent/AU3255897A/en
Application granted granted Critical
Publication of AU717233B2 publication Critical patent/AU717233B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU32558/97A 1996-06-06 1997-06-06 Inhibition of HIV-1 replication by antisense RNA expression Ceased AU717233B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1923296P 1996-06-06 1996-06-06
US60/019232 1996-06-06
PCT/EP1997/002952 WO1997046673A2 (en) 1996-06-06 1997-06-06 Inhibition of hiv-1 replication by antisense rna expression

Publications (2)

Publication Number Publication Date
AU3255897A true AU3255897A (en) 1998-01-05
AU717233B2 AU717233B2 (en) 2000-03-23

Family

ID=21792127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32558/97A Ceased AU717233B2 (en) 1996-06-06 1997-06-06 Inhibition of HIV-1 replication by antisense RNA expression

Country Status (7)

Country Link
EP (1) EP0914423A2 (en)
JP (1) JP2001502884A (en)
AU (1) AU717233B2 (en)
CA (1) CA2254819A1 (en)
IL (1) IL127038A0 (en)
NZ (1) NZ333190A (en)
WO (1) WO1997046673A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
DE60045932D1 (en) * 2000-09-01 2011-06-16 Gen Probe Inc HIV-1 sequence amplification for recognition of sequences related to drug resistance mutations
JP5461460B2 (en) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド Amplification of HIV-1 sequences for detection of sequences associated with drug resistance mutations
JP5461459B2 (en) * 2011-03-01 2014-04-02 ジェン−プローブ・インコーポレーテッド Amplification of HIV-1 sequences for detection of sequences associated with drug resistance mutations
JP2012105648A (en) * 2011-12-12 2012-06-07 Gen Probe Inc Amplification of hiv-1 sequence for sequence detection associated with drug resistant mutation
US9932364B2 (en) 2013-08-26 2018-04-03 The Royal Institution For The Advancement Of Learning/Mcgill University Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2032158C (en) * 1989-05-25 2009-09-15 Helmut Bachmayer Multivalent repressor of gene function
EP0598935A1 (en) * 1992-11-24 1994-06-01 Bayer Ag Expression vectors and their use to produce HIV-resistant human cells for therapeutic use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them

Also Published As

Publication number Publication date
WO1997046673A2 (en) 1997-12-11
IL127038A0 (en) 1999-09-22
AU717233B2 (en) 2000-03-23
JP2001502884A (en) 2001-03-06
NZ333190A (en) 2001-03-30
CA2254819A1 (en) 1997-12-11
WO1997046673A3 (en) 1998-01-15
EP0914423A2 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
AU6479696A (en) Antisense inhibition of hepatitis b virus replication
AU3868699A (en) Antisense modulation of rhoa expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
FI944523A0 (en) Inhibition of papillomavirus by antisense oligonucleotide
AU7972898A (en) Compositions inducing cleavage of rna motifs
AU4314099A (en) Novel method of large scale plasmid purification
AU2001277003A1 (en) Antisense inhibition of her-3 expression
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU1564897A (en) Antisense inhibition of human adhesion molecules
AU4248297A (en) Inhibition of viral replication
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
AU4479096A (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
AU2585197A (en) Antisense approach to gene inhibition
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU6522599A (en) Use of a self-cleaving rna motif to modulate gene expression
AU4971199A (en) Oligonucleotide inhibitors of bcl-xl
NZ324118A (en) Furan-and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants
AU4425397A (en) Antisense gene therapy for rna viruses
AU4663297A (en) Inhibition of hiv replication using soluble tat peptide analogs
AU6378598A (en) Method for inhibition of virus replication
AU7000496A (en) Anti-inflammatory antisense drug
AU2584395A (en) Antisense oligomers for inhibiting human papillomaviruses
AU6578298A (en) Antisense inhibition of angiogenin expression
AU5989396A (en) Origin of replication complex genes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)